Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells

Respiratory Research

Volumn 12, Issue , 2011, Pages

  Ali, Omar F ^a   Growcott, Ellena J ^b   Butrous, Ghazwan S ^c   Wharton, John ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c UNIVERSITY OF KENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ATORVASTATIN; COMPACTIN; ENDOTHELIN 1; FLUINDOSTATIN; GELATINASE B; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; MEVALONIC ACID; NITRIC OXIDE; PRAVASTATIN; RHO KINASE; SILDENAFIL; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; DNA SYNTHESIS; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN CELL; LIPOPHILICITY; PATHOGENESIS; PLEIOTROPY; PULMONARY ARTERY; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENETICS; MALE; MIDDLE AGED; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC PLEIOTROPY; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PRAVASTATIN; PULMONARY ARTERY; PYRROLES; SIMVASTATIN;

EID: 80053971380     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-137     Document Type: Article

References (43)

1. Sadowitz B, Maier KG, Gahtan V. Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg 2010, 44:241-251. 10.1177/1538574410362922, 20403949.
2. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005, 45:89-118. 10.1146/annurev.pharmtox.45.120403.095748, 2694580, 15822172.
3. Nunes KP, Rigsby CS, Webb RC. RhoA/Rho-kinase and vascular diseases: what is the link?. Cell Mol Life Sci 2010, 67:3823-3836. 10.1007/s00018-010-0460-1, 2996825, 20668910.
4. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006, 98:322-334. 10.1161/01.RES.0000201960.04223.3c, 16484628.
5. McMurtry IF, Abe K, Ota H, Fagan KA, Oka M. Rho kinase-mediated vasoconstriction in pulmonary hypertension. Adv Exp Med Biol 2010, 661:299-308. 10.1007/978-1-60761-500-2_19, 20204738.
6. Oka M, Fagan KA, Jones PL, McMurtry IF. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008, 155:444-454. 2579659, 18536743.
7. Ali O, Wharton J, Gibbs JS, Howard L, Wilkins MR. Emerging therapies for pulmonary arterial hypertension. Expert Opin Investig Drugs 2007, 16:803-818. 10.1517/13543784.16.6.803, 17501693.
8. Guilluy C, Sauzeau V, Rolli-Derkinderen M, Guerin P, Sagan C, Pacaud P, Loirand G. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 2005, 146:1010-1018. 10.1038/sj.bjp.0706408, 1751229, 16205723.
9. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, Kao PN. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002, 166:1403-1408. 10.1164/rccm.200203-268OC, 12406854.
10. Girgis RE, Li D, Zhan X, Garcia JG, Tuder RM, Hassoun PM, Johns RA. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003, 285:H938-945.
11. Murata T, Kinoshita K, Hori M, Kuwahara M, Tsubone H, Karaki H, Ozaki H. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 2005, 25:2335-2342. 10.1161/01.ATV.0000186184.33537.48, 16166567.
12. Guerard P, Rakotoniaina Z, Goirand F, Rochette L, Dumas M, Lirussi F, Bardou M. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol 2006, 373:401-414. 10.1007/s00210-006-0082-1, 16896805.
13. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, Burns N, Kasper M, Voelkel NF. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006, 291:L668-676. 10.1152/ajplung.00491.2005, 16698853.
14. Laudi S, Trump S, Schmitz V, West J, McMurtry IF, Mutlak H, Christians U, Weimann J, Kaisers U, Steudel W. Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol 2007, 293:L630-638. 10.1152/ajplung.00110.2006, 17575010.
15. Satoh K, Fukumoto Y, Nakano M, Sugimura K, Nawata J, Demachi J, Karibe A, Kagaya Y, Ishii N, Sugamura K, Shimokawa H. Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc Res 2009, 81:226-234. 10.1093/cvr/cvn244, 18779230.
16. Zhao L, Sebkhi A, Ali O, Wojciak-Stothard B, Mamanova L, Yang Q, Wharton J, Wilkins MR. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J 2009, 34:948-957. 10.1183/09031936.00143508, 19797670.
17. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003, 108:1640-1645. 10.1161/01.CIR.0000087592.47401.37, 12963647.
18. Girgis RE, Mozammel S, Champion HC, Li D, Peng X, Shimoda L, Tuder RM, Johns RA, Hassoun PM. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007, 292:L1105-1110. 10.1152/ajplung.00411.2006, 17277047.
19. Wilkins MR, Ali O, Bradlow W, Wharton J, Taegtmeyer A, Rhodes CJ, Ghofrani HA, Howard L, Nihoyannopoulos P, Mohiaddin RH, Gibbs JS. Simvastatin Pulmonary Hypertension Trial (SiPHT) Study Group: Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med 2010, 181:1106-1113. 2874452, 20460548.
20. Rakotoniaina Z, Guerard P, Lirussi F, Goirand F, Rochette L, Dumas M, Bardou M. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin. Naunyn Schmiedebergs Arch Pharmacol 2006, 374:195-206. 10.1007/s00210-006-0112-z, 17102939.
21. McMurtry MS, Bonnet S, Michelakis ED, Bonnet S, Haromy A, Archer SL. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol 2007, 293:L933-940. 10.1152/ajplung.00310.2006, 17675370.
22. Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000, 102:3130-3136.
23. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, Wharton J. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002, 165:398-405.
24. Growcott EJ, Spink KG, Ren X, Afzal S, Banner KH, Wharton J. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respir Res 2006, 7:9. 10.1186/1465-9921-7-9, 1386664, 16423283.
25. Ongini E, Impagnatiello F, Bonazzi A, Guzzetta M, Govoni M, Monopoli A, Del Soldato P, Ignarro LJ. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Natl Acad Sci USA 2004, 101:8497-8502. 10.1073/pnas.0401996101, 420422, 15173604.
26. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005, 172:105-113. 10.1164/rccm.200411-1587OC, 15817798.
27. Wort SJ, Woods M, Warner TD, Evans TW, Mitchell JA. Cyclooxygenase-2 acts as an endogenous brake on endothelin-1 release by human pulmonary artery smooth muscle cells: implications for pulmonary hypertension. Mol Pharmacol 2002, 62:1147-1153. 10.1124/mol.62.5.1147, 12391278.
28. Takeda N, Kondo M, Ito S, Ito Y, Shimokata K, Kume H. Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Am J Respir Cell Mol Biol 2006, 35:722-729. 10.1165/rcmb.2006-0034OC, 16858009.
29. Vigano T, Hernandez A, Corsini A, Granata A, Belloni P, Fumagalli R, Paoletti R, Folco G. Mevalonate pathway and isoprenoids regulate human bronchial myocyte proliferation. Eur J Pharmacol 1995, 291:201-203. 10.1016/0922-4106(95)90143-4, 8566171.
30. Martinez-Gonzalez J, Vinals M, Vidal F, Llorente-Cortes V, Badimon L. Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells. Atherosclerosis 1997, 135:213-223. 10.1016/S0021-9150(97)00164-0, 9430371.
31. Kawut SM, Bagiella E, Lederer DJ, Shimbo D, Horn EM, Roberts KE, Hill NS, Barr RG, Rosenzweig EB, Post W, et al. Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension: ASA-STAT. Circulation
32. Sauzeau V, Rolli-Derkinderen M, Marionneau C, Loirand G, Pacaud P. RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J Biol Chem 2003, 278:9472-9480. 10.1074/jbc.M212776200, 12524425.
33. Jurasz P, Courtman D, Babaie S, Stewart DJ. Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials. Pharmacol Ther 2010, 126:1-8. 10.1016/j.pharmthera.2009.12.006, 20117135.
34. Huang JB, Liu YL, Sun PW, Lv XD, Bo K, Fan XM. Novel strategy for treatment of pulmonary arterial hypertension: enhancement of apoptosis. Lung 2010, 188:179-189. 10.1007/s00408-010-9233-8, 20213196.
35. Filippatos GS, Gangopadhyay N, Lalude O, Parameswaran N, Said SI, Spielman W, Uhal BD. Regulation of apoptosis by vasoactive peptides. Am J Physiol Lung Cell Mol Physiol 2001, 281:L749-761.
36. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000, 87:616-622.
37. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 2005, 112:423-431. 10.1161/CIRCULATIONAHA.105.540542, 16027270.
38. George J, D'Armiento J. Transgenic expression of human matrix metalloproteinase-9 augments monocrotaline-induced pulmonary arterial hypertension in mice. J Hypertens 2010,
39. Frisdal E, Gest V, Vieillard-Baron A, Levame M, Lepetit H, Eddahibi S, Lafuma C, Harf A, Adnot S, Dortho MP. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J 2001, 18:838-845. 10.1183/09031936.01.00084601, 11757635.
40. Lepetit H, Eddahibi S, Fadel E, Frisdal E, Munaut C, Noel A, Humbert M, Adnot S, D'Ortho MP, Lafuma C. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J 2005, 25:834-842. 10.1183/09031936.05.00072504, 15863640.
41. Turner NA, O'Regan DJ, Ball SG, Porter KE. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. Faseb J 2005, 19:804-806.
42. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006, 112:71-105. 10.1016/j.pharmthera.2006.03.003, 16714062.
43. Ikeda T, Nakamura K, Akagi S, Kusano KF, Matsubara H, Fujio H, Ogawa A, Miura A, Miura D, Oto T, et al. Inhibitory effects of simvastatin on platelet-derived growth factor signaling in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol 2010, 55:39-48. 10.1097/FJC.0b013e3181c0419c, 19786891.